Drug Profile
Research programme: orthopaedic stem cell therapies - BioE/Phillips Plastics
Alternative Names: MLPCLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BioE; Phillips Plastics Corporation
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA
- 24 May 2007 Preclinical trials in Bone disorders in USA (unspecified route)